Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024)
Aytu Biopharma's (AYTU) quarterly Liabilities from Discontinued Operations came in at 557000.0 in Q2 2024.
Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024) Analysis & Trends
Aytu Biopharma (AYTU) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 557000.0 in Q2 2024.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 557000.0 in Q2 2024; TTM through Jun 2024 was 557000.0, a N/A change from a year earlier, with the FY2024 full-year figure at 557000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q2 2024 stood at 557000.0.
- Over the last five years, Liabilities from Discontinued Operations for AYTU reached as high as 557000.0 in Q2 2024 and fell as low as 557000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Aytu Biopharma | 1.43 Mn | -25.28 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 557,000.00 |
| Jun 30, 2024 | 557,000.00 |